āĻšā§‹āĻŽZEGA â€ĸ FRA
AstraZeneca PLC
ā§Ŧ⧍.ā§Ļā§Ļâ‚Ŧ
⧍ āĻŽā§‡, ā§§ā§Ļ:ā§Ģ⧝:ā§Ģā§§ PM GMT +⧍ · EUR · FRA · āĻĄāĻŋāϏāĻ•ā§āϞ⧇āĻŽāĻžāϰ
āĻ¸ā§āϟāĻ•DE-āĻ āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋGB-āĻ āĻšā§‡āĻĄāĻ•ā§‹ā§ŸāĻžāĻ°ā§āϟāĻžāϰ
āĻ•āĻžāϞ āĻļ⧇āώ āϝ⧇ āĻĻāĻžāĻŽā§‡ āĻ›āĻŋāϞ
ā§Ŧā§Š.ā§Ļā§Ļâ‚Ŧ
āϏāĻžāϰāĻž āĻĻāĻŋāύ⧇āϰ āĻŸā§āϰ⧇āĻĄāĻŋāĻ‚ā§Ÿā§‡ āĻ¸ā§āϟāϕ⧇āϰ āĻĻāĻžāĻŽā§‡āϰ āĻ“āĻ āĻž āύāĻžāĻŽāĻžāϰ āϰ⧇āĻžā§āϜ
ā§Ŧ⧍.ā§Ļā§Ļâ‚Ŧ - ā§Ŧ⧍.ā§Ļā§Ļâ‚Ŧ
āϏāĻžāϰāĻž āĻŦāĻ›āϰ⧇āϰ āϰ⧇āĻžā§āϜ
ā§Ģā§­.ā§Ģā§Ļâ‚Ŧ - ⧭⧝.ā§Ģā§Ļâ‚Ŧ
āĻŽāĻžāĻ°ā§āϕ⧇āϟ āĻ•ā§āϝāĻžāĻĒ
⧍⧍ā§Ģ.⧍ā§Ļāϕ⧋ USD
āĻ—āĻĄāĻŧ āĻ­āϞāĻŋāωāĻŽ
⧍ā§Ē.ā§Ļā§Ļ
P/E āĻ…āύ⧁āĻĒāĻžāϤ
-
āϞāĻ­ā§āϝāĻžāĻ‚āĻļ āĻĒā§āϰāĻĻāĻžāύ
-
āĻ–āĻŦāϰ⧇ āĻ°ā§Ÿā§‡āϛ⧇
āĻĢāĻžāχāύāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒāĻžāϰāĻĢāĻ°ā§āĻŽā§āϝāĻžāĻ¨ā§āϏ
āĻ†ā§Ÿā§‡āϰ āĻ¸ā§āĻŸā§‡āϟāĻŽā§‡āĻ¨ā§āϟ
āωāĻĒāĻžāĻ°ā§āϜāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
(USD)āĻŽāĻžāĻ°ā§āϚ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āωāĻĒāĻžāĻ°ā§āϜāύ
ā§§ā§Š.ā§Ģ⧝āĻļāĻ¤Â āϕ⧋⧭.ā§§ā§­%
āĻŦā§āϝāĻŦāϏāĻž āϚāĻžāϞāĻžāύ⧋āϰ āĻ–āϰāϚ
ā§­ā§Ģā§Ģ.⧝ā§Ļ āϕ⧋⧍.⧝ā§Ļ%
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
⧍⧝⧧.ā§Ŧā§Ļ āĻ•ā§‹ā§Šā§Š.ā§Žā§¨%
āύ⧇āϟ āĻĒā§āϰāĻĢāĻŋāϟ āĻŽāĻžāĻ°ā§āϜāĻŋāύ
⧍⧧.ā§Ēā§Ŧ⧍ā§Ē.ā§Žā§Ē%
āĻļā§‡ā§ŸāĻžāϰ āĻĒā§āϰāϤāĻŋ āωāĻĒāĻžāĻ°ā§āϜāύ
ā§§.⧍ā§Ē⧍ā§Ļ.ā§Žā§­%
EBITDA
ā§Ģā§Ļā§Ž.ā§Ļā§Ļ āϕ⧋⧧ā§Ŧ.⧍ā§Ģ%
āĻĒā§āϰāϝ⧋āĻœā§āϝ āĻŸā§āϝāĻžāĻ•ā§āϏ⧇āϰ āĻšāĻžāϰ
ā§§ā§Ē.ā§§ā§Ē%—
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
(USD)āĻŽāĻžāĻ°ā§āϚ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āĻ•ā§āϝāĻžāĻļ āĻ“ āĻ•āĻŽ āϏāĻŽā§Ÿā§‡āϰ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—
ā§Ģā§Šā§¯.ā§Ģā§Ļ āϕ⧋-ā§Šā§¨.ā§­ā§Ē%
āĻŽā§‹āϟ āϏāĻŽā§āĻĒāĻĻ
ā§§ā§Ļā§Ŧ.⧍ā§ĢāĻ•ā§‹ā§Š.ā§Žā§­%
āĻŽā§‹āϟ āĻĻāĻžā§Ÿ
ā§Ŧā§Ģ.⧧⧍āĻļāĻ¤Â āϕ⧋ā§Ļ.ā§Ģā§§%
āĻŽā§‹āϟ āχāϕ⧁āχāϟāĻŋ
ā§Ēā§§.ā§§ā§ŠāĻļāĻ¤Â āĻ•ā§‹â€”
āφāωāϟāĻ¸ā§āĻŸā§āϝāĻžāĻ¨ā§āĻĄāĻŋāĻ‚ āĻļā§‡ā§ŸāĻžāϰ
ā§§ā§Ģā§Ģ.ā§Ļā§Ļ āĻ•ā§‹â€”
āĻĒā§āϰāĻžāχāϏ āϟ⧁ āĻŦ⧁āĻ• āϰ⧇āĻļāĻŋāĻ“
⧍.ā§Šā§Žâ€”
āϏāĻŽā§āĻĒāĻĻ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
⧝.ā§Ļā§Š%—
āĻŽā§‚āϞāϧāύ āĻĨ⧇āϕ⧇ āĻ†ā§Ÿ
ā§§ā§Š.ā§§ā§Ŧ%—
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
(USD)āĻŽāĻžāĻ°ā§āϚ ⧍ā§Ļ⧍ā§ĢY/Y āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
āύ⧇āϟ āχāύāĻ•āĻžāĻŽ
⧍⧝⧧.ā§Ŧā§Ļ āĻ•ā§‹ā§Šā§Š.ā§Žā§¨%
āĻ…āĻĒāĻžāϰ⧇āĻļāύ āĻĨ⧇āϕ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āĻ•ā§āϝāĻžāĻļ
ā§Šā§­ā§§.ā§Šā§Ļ āϕ⧋ā§Ē⧝.ā§Šā§Ŧ%
āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
-⧧⧍ā§Ģ.ā§Šā§Ļ āϕ⧋ā§Ēā§Ž.ā§Ļā§­%
āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋāĻ‚ āĻĨ⧇āϕ⧇ āĻĒā§āϰāĻžāĻĒā§āϤ āĻ•ā§āϝāĻžāĻļ
-⧍⧭ā§Ļ.ā§­ā§Ļ āϕ⧋-ā§¨ā§Šā§Š.ā§Ēā§Ž%
āύāĻ—āĻĻ⧇ āĻŽā§‹āϟ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ
-⧍⧍.⧍ā§Ļ āϕ⧋-ā§§ā§§ā§Ļ.ā§Žā§Ļ%
āĻĢā§āϰāĻŋ āĻ•ā§āϝāĻžāĻļ āĻĢā§āϞ⧋
⧍⧍ā§Ē.ā§Ģā§Ē āϕ⧋ā§Ŧā§Ģ.ā§§ā§Š%
āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, United Kingdom. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, United Kingdom; Gothenburg, Sweden and Gaithersburg in Maryland, U.S. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in SÃļdertälje. Throughout the twentieth century, it grew into the largest pharmaceutical company in Sweden. Wikipedia
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāϤ āĻšā§Ÿā§‡āϛ⧇
ā§Ŧ āĻāĻĒā§āϰāĻŋ, ⧧⧝⧝⧝
āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāϟ
āĻ•āĻ°ā§āĻŽāϚāĻžāϰ⧀
⧝ā§Ē,ā§Šā§Ļā§Ļ
āφāϰāĻ“ āĻĻ⧇āϖ⧁āύ
āφāĻĒāύāĻžāϰ āĻšā§ŸāϤ āĻĒāĻ›āĻ¨ā§āĻĻ āĻšāĻŦ⧇
āϏāĻŽā§āĻĒā§āϰāϤāĻŋ āĻ•āϰāĻž āϏāĻžāĻ°ā§āϚ, āĻĢāϞ⧋ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋ āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ…ā§āϝāĻžāĻ•ā§āϟāĻŋāĻ­āĻŋāϟāĻŋ āĻĨ⧇āϕ⧇ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϟāĻŋ āĻœā§‡āύāĻžāϰ⧇āϟ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ

āϏāĻŽāĻ¸ā§āϤ āĻĄā§‡āϟāĻž āĻ“ āϤāĻĨā§āϝ "āϝ⧇āĻŽāύāĻ­āĻžāĻŦ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āϗ⧇āϛ⧇, āĻ āĻŋāĻ• āϤ⧇āĻŽāύāĻ­āĻžāĻŦ⧇" āĻļ⧁āϧ⧁āĻŽāĻžāĻ¤ā§āϰ āĻŦā§āϝāĻ•ā§āϤāĻŋāĻ—āϤ āϤāĻĨā§āϝ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻĒā§āϰāĻĻāĻžāύ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇ āĻāĻŦāĻ‚ āĻļā§‡ā§ŸāĻžāϰ āĻŸā§āϰ⧇āĻĄāĻŋāĻ‚ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ, āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ—, āĻŸā§āϝāĻžāĻ•ā§āϏ, āφāχāύāĻŋ āĻŦāĻŋāώ⧟, āĻ…ā§āϝāĻžāĻ•āĻžāωāĻ¨ā§āϟāĻŋāĻ‚ āĻŦāĻž āĻ…āĻ¨ā§āϝ āϕ⧋āύāĻ“ āĻĒāϰāĻžāĻŽāĻ°ā§āĻļ āĻŦāĻž āωāĻĒāĻĻ⧇āĻļ āĻĻ⧇āĻ“ā§ŸāĻžāϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āϤāĻž āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤ Google āϕ⧋āύāĻ“ āĻŦāĻŋāύāĻŋā§Ÿā§‹āĻ— āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āωāĻĒāĻĻ⧇āĻˇā§āϟāĻž āύ⧟ āĻāĻŦāĻ‚ āĻāχ āϤāĻžāϞāĻŋāĻ•āĻžāϤ⧇ āĻ…āĻ¨ā§āϤāĻ°ā§āϭ⧁āĻ•ā§āϤ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋ āĻ…āĻĨāĻŦāĻž āϏ⧇āχāϏāĻŦ āϕ⧋āĻŽā§āĻĒāĻžāύāĻŋāϰ āχāĻ¸ā§āϝ⧁ āĻ•āϰāĻž āϏāĻŋāĻ•āĻŋāωāϰāĻŋāϟāĻŋāϰ āĻŦā§āϝāĻžāĻĒāĻžāϰ⧇ āϕ⧋āύāĻ“ āϰāĻ•āĻŽ āĻŽāϤāĻžāĻŽāϤ āĻŦā§āϝāĻ•ā§āϤ āĻ•āϰ⧇ āύāĻžāĨ¤ āϝ⧇āϕ⧋āύāĻ“ āϧāϰāύ⧇āϰ āĻŸā§āϰ⧇āĻĄ āĻ•āϰāĻžāϰ āφāϗ⧇, āĻŽā§‚āĻ˛ā§āϝ āϝāĻžāϚāĻžāχ āĻ•āϰ⧇ āύ⧇āĻ“ā§ŸāĻžāϰ āϜāĻ¨ā§āϝ āφāĻĒāύāĻžāϰ āĻŦā§āϰ⧋āĻ•āĻžāϰ āĻŦāĻž āĻĢāĻžāχāĻ¨ā§āϝāĻžāĻ¨ā§āϏāĻŋ⧟āĻžāϞ āĻĒā§āϰāϤāĻŋāύāĻŋāϧāĻŋāϰ āϏāĻžāĻĨ⧇ āφāϞ⧋āϚāύāĻž āĻ•āϰ⧇ āύāĻŋāύāĨ¤ āφāϰāĻ“ āϜāĻžāύ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻ•āϰ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŽā§āϛ⧁āύ
āϏāĻžāĻ°ā§āϚ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧁āύ
Google āĻ…ā§āϝāĻžāĻĒā§āϞāĻŋāϕ⧇āĻļāĻžāύāϗ⧁āϞāĻŋ
āĻĒā§āϰāϧāĻžāύ āĻŽā§‡āύ⧁